European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 619-624 , December 2008

A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients

  • Simeon Metallidis

      Affiliations

    • 1st Internal Medicine Department, Infectious Diseases Division, AHEPA University Hospital, Thessaloniki, Greece
    • Corresponding Author InformationCorresponding author. First Department of Internal Medicine, Infectious Diseases Division, AHEPA University Hospital, 1 Stilponos Kyrialidi Str. PC 54006, Thessaloniki, Greece. Tel.: +30 2310994619, +30 6944 361931(mobile); fax: +30 2310994615.
    • ,
  • Panagiotis Kollaras

      Affiliations

    • 1st Internal Medicine Department, Infectious Diseases Division, AHEPA University Hospital, Thessaloniki, Greece
    • ,
  • Theodoros Giannakakis

      Affiliations

    • First Department of Medical Oncology, Agii Anaryri Cancer Hospital, Athens, Greece
    • ,
  • Basilis Seitanidis

      Affiliations

    • Oncology Division, Metaxa Hospital, Piraeus, Greece
    • ,
  • Theodoros Kordosis

      Affiliations

    • Oncology Division, Laikon General Hospital, Athens, Greece
    • ,
  • John Nikolaidis

      Affiliations

    • 1st Internal Medicine Department, Infectious Diseases Division, AHEPA University Hospital, Thessaloniki, Greece
    • ,
  • Apostolos Hatzitolios

      Affiliations

    • 1st Internal Medicine Department, Infectious Diseases Division, AHEPA University Hospital, Thessaloniki, Greece
    • ,
  • Pavlos Nikolaidis

      Affiliations

    • 1st Internal Medicine Department, Infectious Diseases Division, AHEPA University Hospital, Thessaloniki, Greece

Received 22 February 2007 ,Revised 3 June 2007 ,Accepted 13 August 2007.

References 

  1. Klastersky J. Febrile neutropenia. Curr Opin Oncol. 1993;5:625–632
  2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323–1332
  3. Klastersky J. Empirical treatment of sepsis in neutropenic patients. Int J Antimicrob Agents. 2000;16:131–133
  4. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis. 1993;17(Suppl 2):S378–S384
  5. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother. 1998;41(Suppl D):65–80
  6. Klastersky J. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997]. Rev Med Brux. 1997;18:323–327
  7. Burney IA, Farooqui BJ, Siddiqui T, Khurshid M. The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy. J Pak Med Assoc. 1998;48:364–367
  8. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494
  9. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29:503–507
  10. Nucci M, Pulcheri WA, Spector N, de Oliveira HP. Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients. J Infect. 1994;28:335–336
  11. Santhosh-Kumar CR, Ajarim DS, Harakati MS, al Momen AK, al Mohareb F, Zeitany RG. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia. J Infect. 1992;25:11–19
  12. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994;120:834–844
  13. Bodey GP, Rolston KV, Raad II. Ciprofloxacin versus tobramycin for neutropenic fevers. Ann Intern Med. 2003;138:435;author reply 436
  14. Pérez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J, et al. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients]. Rev Med Chil. 1995;123(3):312–320
  15. Hazel DL, Graham J, Dickinson JP, Newland AC, Kelsey SM. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother. 1997;9:267–272
  16. Paesmans M. Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia. Support Care Cancer. 1998;6:438–443
  17. Karthaus M, Cornely OA. Ceftriaxone in febrile neutropenia. J Chemother. 2003;15:211–219
  18. Karthaus M, Egerer G, Kullmann KH, Ritter J, Jurgens H. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis. 1998;17:501–504
  19. Sahu S, Bapna A, Pai SK, Nair CN, Kurkure PA, Advani SH. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol. 1997;14:205–211
  20. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer . Efficacy and toxicity of single-daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann. Intern. Med. 1993;584–593
  21. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515–521
  22. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34:87–91

PII: S0953-6205(08)00082-4

doi: 10.1016/j.ejim.2007.08.011

European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 619-624 , December 2008

Article Tools